I too question myself if I am missing something regularly, but like you I can’t find anything. Sure maybe I’m overly optimistic about cancer, combo launch, etc. but even if wrong I can’t see being so wrong where this stock won’t be significantly higher than our current share price. I run the numbers only based on combo approval and even licensed at 15% and fully diluted to 700M shares, with a normal valuation of 4 P/S or 10-15 PE we are worth multiples of where we currently trade. If/once anything else is successful and our financial concerns cleared up the valuation multiplies exponentially.

I think once we are able to uplist that will change everything. I truly believe that the word is not out and analysts coverage and institutional buyers will change that. Obviously we have a ways to go to be uplist eligible (organically I hope), but that time is coming pretty soon. This should be a fun ride for a few years once we crack the code.